CA
UTHR icon

CoreCap Advisors’s United Therapeutics UTHR Stock Holding History

CoreCap Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.1K Sell
85
-56
-40% -$31.5K ﹤0.01% 1443
2026
Q1 		$83.6K Buy
141
+124
+729% +$61.8K ﹤0.01% 1097
2025
Q4 		$8.28K Sell
17
-8
-32% -$3.73K ﹤0.01% 2028
2025
Q3 		$10.5K Buy
25
+2
+9% +$673 ﹤0.01% 1915
2025
Q2 		$6.61K Sell
23
-71
-76% -$21.2K ﹤0.01% 2031
2025
Q1 		$29K Buy
94
+71
+309% +$24.3K ﹤0.01% 1388
2024
Q4 		$8.12K Buy
23
+8
+53% +$2.94K ﹤0.01% 1849
2024
Q3 		$5.38K Hold
15
– – ﹤0.01% 1958
2024
Q2 		$4.78K Buy
+15
New +$3.97K ﹤0.01% 1180

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CoreCap Advisors's UTHR Position: Q2 2026 in Review

CoreCap Advisors reduced its United Therapeutics (UTHR) stake by 40% in Q2 2026, selling an estimated $31.5K and leaving 85 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

CoreCap Advisors first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $83.6K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • CoreCap Advisors held 85 shares of United Therapeutics worth $46.1K as of Q2 2026.
  • CoreCap Advisors sold 56 United Therapeutics shares in Q2 2026, an estimated $31.5K.
  • United Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1443 holding.
  • CoreCap Advisors first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • CoreCap Advisors's United Therapeutics position peaked at $83.6K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.